Mineralys Therapeutics (MLYS) Research & Development (2022 - 2026)
Mineralys Therapeutics (MLYS) reported Research & Development of $22.67 million for Q3 2026, down 27.9% from $31.45 million a year earlier and down 89.8% from the prior quarter.
Powered by 
Analysis
Mineralys Therapeutics (MLYS) Research & Development (2022 - 2026) Analysis & Trends
Over the twelve months ended Sep 30, 2026, Mineralys Therapeutics' Research & Development came in at $292.81 million, up 92.4% year-over-year; for FY2025, it was $132.01 million, down 21.7% from FY2024.
- Research & Development has a three-year compound annual growth rate of 71.3% (FY2022 to FY2025).
- By year, Research & Development came in at $168.58 million in FY2024 (+139.6%), $70.36 million in FY2023 (+168.0%) and $26.25 million in FY2022.
- The Q3 2026 figure ranks as the lowest quarterly Research & Development since Q3 2023.
- Year over year, Research & Development gained in three of the last eight quarters, with growth averaging 54.6%.
- The high point for year-over-year Research & Development in five years was Q2 2026 (growth of 478.3%); the low point was Q4 2025 (a decline of 45.2%).
- Per Business Quant data, the three quarters before Q3 2026 came in at $221.38 million (Q2 2026), $24.37 million (Q1 2026) and $24.4 million (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,264.65 Bn | 1,238.27 Bn | 20.46 Bn | 4.25 Bn |
| 2 | Johnson & Johnson | 677.74 Bn | 597.60 Bn | 17.30 Bn | 4.65 Bn |
| 3 | AbbVie | 517.10 Bn | 485.11 Bn | 13.12 Bn | 2.57 Bn |
| 4 | Merck | 362.23 Bn | 325.17 Bn | 13.19 Bn | 4.54 Bn |
| 5 | Novartis Ag | 315.90 Bn | 276.16 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 289.40 Bn | 266.24 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 249.90 Bn | 201.56 Bn | 7.58 Bn | 2.11 Bn |
| 8 | Gilead Sciences | 209.15 Bn | 184.26 Bn | 6.73 Bn | 1.61 Bn |
| 9 | Pfizer | 165.88 Bn | 113.23 Bn | 12.56 Bn | 3.02 Bn |
| 10 | Mineralys Therapeutics | 1.42 Bn | -1.17 Bn | - | 22.67 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 22.67 Mn |
| Jun 30, 2026 | 221.38 Mn |
| Mar 31, 2026 | 24.37 Mn |
| Dec 31, 2025 | 24.40 Mn |
| Sep 30, 2025 | 31.45 Mn |
| Jun 30, 2025 | 38.28 Mn |
| Mar 31, 2025 | 37.88 Mn |
| Dec 31, 2024 | 44.57 Mn |
| Sep 30, 2024 | 53.99 Mn |
| Jun 30, 2024 | 39.27 Mn |
| Mar 31, 2024 | 30.75 Mn |
| Dec 31, 2023 | 23.69 Mn |
| Sep 30, 2023 | 22.50 Mn |
| Jun 30, 2023 | 11.88 Mn |
| Mar 31, 2023 | 12.29 Mn |
| Dec 31, 2022 | 7.82 Mn |
| Sep 30, 2022 | 6.06 Mn |
| Jun 30, 2022 | 5.60 Mn |
| Mar 31, 2022 | 6.78 Mn |
API Access
Mineralys Therapeutics Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=MLYS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "MLYS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=MLYS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();